New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
NCT ID NCT07705035
First seen Jul 15, 2026 · Last updated Jul 24, 2026 · Updated 3 times
Summary
This early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the drug works. The main goals are to check safety, measure how the drug moves through the body, and look for signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental biologic drug called DBC-664
- What this could lead to
- If successful, this could lead to a new treatment option for several types of advanced solid tumors that have not responded to other therapies.
- What could go wrong
- This is a very early, first-in-human trial focused mainly on safety, so it is unknown whether DBC-664 will effectively shrink tumors or improve survival. Side effects are also not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
START New Jersey
RECRUITINGEast Brunswick, New Jersey, 08816, United States
-
START New York
RECRUITINGLake Success, New York, 11402, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- A safer first cut? trial tests two laparoscopic entry points for endometrial cancer surgery
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?